Evidence map›Paper›PMID 23572188›Full record

SynthesisGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2014

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association.

Hideaki Shimada, Tamaki Noie, Manabu Ohashi, Koji Oba, Yutaka Takahashi

Registry-linked trialOpen access · bronzeAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06342427 (Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA), which is not on this map. Cited by 323 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
323citing papers in PubMed, 7 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06342427 completednot on this mapstarted 2023, after this paper: background citation

Early Detection of Stomach Cancer With a Liquid Biopsy Based on Exosomal Micro-RNA

TypeobservationalSponsorCity of Hope Medical CenterRan2023 to 2024Enrolled809ConditionsGastric Cancer, Gastric Adenocarcinoma, Gastric Cancer Stage, Gastric NeoplasmArmsDESTINEX
3 · Its place in the literature

Who cites it

323 citing papers in PubMed, 7 syntheses or guidelines pooled it, 536 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

263 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Hideaki ShimadaDepartment of Surgery, School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan, hideaki.shimada@med.toho-u.ac.jp.
Tamaki Noie
Manabu Ohashi
Koji Oba
Yutaka Takahashi
Hokkaido University Hospital · JPInternational University of Health and Welfare · JPNTT Medical Center · JPToho University · JPTokyo Metropolitan Komagome Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this review was to evaluate the clinical significance of serum tumor markers, particularly CEA, CA19-9, and CA72-4, in patients with gastric cancer. A systematic literature search was performed using PubMed/MEDLINE with the keywords "gastric cancer" and "tumor marker," to select 4,925 relevant reports published before the end of November 2012. A total of 187 publications contained data for CEA and CA19-9, and 19 publications contained data related to all three tumor markers. The positive rates were 21.1 % for CEA, 27.8 % for CA19-9, and 30.0 % for CA72-4. These three markers were significantly associated with tumor stage and patient survival. Serum markers are not useful for early cancer, but they are useful for detecting recurrence and distant metastasis, predicting patient survival, and monitoring after surgery. Tumor marker monitoring may be useful for patients after surgery because the positive conversion of tumor markers usually occurs 2-3 months before imaging abnormalities. Among other tumor markers, alpha-fetoprotein (AFP) is useful for detecting and predicting liver metastases. Moreover, CA125 and sialyl Tn antigens (STN) are useful for detecting peritoneal metastases. Although no prospective trial has yet been completed to evaluate the clinical significance of these serum markers, this literature survey suggests that combinations of CEA, CA19-9, and CA72-4 are the most effective ways for staging before surgery or chemotherapy. In particular, monitoring tumor markers that were elevated before surgery or chemotherapy could be useful for detection of recurrence or evaluation of the response.

Indexed as

alpha-FetoproteinsAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCarcinoembryonic AntigenHumansLiver NeoplasmsNeoplasm Recurrence, LocalStomach NeoplasmsAFP protein, humanalpha-FetoproteinsAntigens, Tumor-Associated, CarbohydrateBiomarkers, TumorCA-125 AntigenCA-19-9 AntigenCA-72-4 antigenCarcinoembryonic Antigensialosyl-Tn antigen

Identifiers

PMID23572188
OpenAlexW2053354145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.